DEFA14A: Masimo Responds to Politan Capital's Director Nominations and Refutes 'False Claims'

Masimo defends against Politan Capital's attempt to gain control of the board, asserting that Politan's actions are not in the best interests of stockholders or patients.

Summary

• Masimo has responded to Politan Capital's nomination of two director candidates for the 2024 Annual Meeting.
• Masimo believes Politan's efforts to take control of the Board and unseat CEO Joe Kiani are against the best interests of stockholders and patients.
• Masimo claims that Politan's Managing Partner, Quentin Koffey, is attempting to take control despite initially claiming to seek only a minority voice.
• Masimo refutes several claims made by Politan, including allegations of exclusion from Board meetings, denial of information, and lack of details on the proposed separation of the consumer business.
• Masimo states that Koffey and Brennan have attended all 11 Board meetings since joining, and Koffey also attends Nominating, Compliance and Corporate Governance Committee meetings as an invited guest.
• Masimo asserts that Koffey and Brennan have received thousands of pages of documents and have had numerous discussions with Masimo's CEO, CFO, and senior management.
• Masimo clarifies that the Board has been engaged in discussions regarding the potential separation of the consumer business since January.
• Masimo emphasizes that the Board reviews and discusses the Company's annual operating plan and guidance, and the Compensation Committee approves financial targets.
• Masimo highlights the appointment of four new independent directors in the past nine months, including two nominated by Politan.
• Masimo assures that the proposed separation would result in a full deconsolidation of the financial statements for the two businesses.
• Masimo claims that Politan rushed the announcement of its nominations to take credit for the positive market reaction following the separation announcement.
• The Masimo Board will review Politan's proposed nominees and present its recommendations in the definitive proxy materials.
• Masimo stockholders are not required to take action at this time.

Sentiment

Score: 4

Explanation: The document has a defensive tone as Masimo is responding to a challenge from an activist investor. While the company presents a confident front, the situation introduces uncertainty and potential disruption.

Positives

• Masimo has seated four new independent directors in the past nine months, constituting two-thirds of the Board.
• The Board is actively involved in evaluating the separation of the consumer business.
• Masimo is committed to pursuing a separation that would result in two separate companies having the best chance at future success.

Negatives

• Politan Capital is attempting to gain control of Masimo's board, leading to potential disruption.
• Masimo accuses Politan of making misleading claims and pursuing a destructive path.
• The company is engaged in a proxy fight, which can be costly and distracting for management.

Risks

• Uncertainties regarding future actions that may be taken by Politan.
• Potential cost and management distraction attendant to Politan's nomination of director nominees.
• The outcome of the proxy fight could impact the company's strategic direction and management.

Future Outlook

The company is focused on the potential separation of its consumer business and the upcoming 2024 Annual Meeting of Stockholders. The outcome of the proxy contest with Politan Capital will likely influence the company's future direction.

Management Comments

• Joe Kiani is committed to pursuing a separation that would result in two separate companies (consumer and healthcare) having the best chance at future success.

Industry Context

This announcement reflects increasing activist investor activity in the healthcare technology sector, where companies with complex structures or perceived undervaluation are targeted for strategic changes.

Comparison to Industry Standards

• Proxy fights are common when activist investors like Politan Capital seek board representation to influence company strategy, similar to situations seen with other companies like Pershing Square's involvement with Target or Carl Icahn's campaigns with various corporations.
• The proposed separation of Masimo's consumer business mirrors moves by other conglomerates to streamline operations and unlock value, such as Johnson & Johnson's spin-off of its consumer health division (Kenvue).
• The level of detail provided in Masimo's response to Politan's claims is typical of companies defending against activist campaigns, aiming to reassure shareholders and counter the activist's narrative, similar to how companies like Procter & Gamble have responded to Trian Fund Management's proposals.

Stakeholder Impact

• The outcome of the proxy fight could impact shareholder value.
• The potential separation of the consumer business could affect employees in both the healthcare and consumer divisions.
• The company's ability to innovate and serve patients could be impacted by the ongoing dispute.

Next Steps

• The Masimo Board and its Nominating, Compliance and Corporate Governance Committee will review Politan's proposed nominees.
• Masimo will file definitive proxy materials with the SEC and mail them to stockholders.
• The Company will announce details regarding the 2024 Annual Meeting in due course.

Key Dates

Keywords

Masimo, Politan Capital, Board of Directors, Proxy Fight, Director Nomination, Corporate Governance, Separation, Stockholders, Joe Kiani